The David H. Koch Institute for Integrative Cancer Research At MIT

About

  • Leadership Council
  • Director's Message
  • Future
  • Scientific Advisory Board
  • FAQs
  • Administration

Faculty

Research

  • KI Approaches to Cancer
  • NCI Research Programs

facilities

  • The Koch Institute
  • Core Facilities

News and Events

  • Grants and Fellowships
  • Cancer Solutions Newsletter
  • Press Kit
  • Summer Symposium

Contact

Support

  • Make a Gift Now
  • Naming Opportunities
  • Bequests and Trusts
  • Corporate Giving
  • Gifts of Stock
  • Gifts of Other Assets

Research

Skip to content

  • KI Approaches to Cancer
    • Nanotechnology Therapy
    • Detection and Monitoring
    • Metastasis
    • Pathways and Resistance
    • Immune System
  • NCI Research Programs

MIT-Harvard NanoMedical Consortium

The MIT-Harvard NanoMedical Consortium is collaboration among MIT, Harvard University, Harvard Medical School, Massachusetts General Hospital, and Brigham and Women’s Hospital. It is one of seven Centers of Cancer Nanotechnology Excellence awarded by the The National Cancer Institute (NCI), part of the National Institutes of Health (NIH). It focuses on developing a diversified portfolio of nanoscale devices for targeted delivery of cancer therapies, diagnostics, non-invasive imaging, and molecular sensing. In addition to general oncology applications, the Consortium focuses on prostate, brain, lung, ovarian, and colon cancer.

Examples of projects that the Consortium is undertaking include the development of:

  • Targeted nanoparticles for treating prostate cancer
  • Polymer nanoparticles and quantum dots for siRNA delivery
  • Next-generation magnetic nanoparticles for multimodal, non-invasive tumor imaging
  • Implantable, biodegradable microelectromechanical systems (MEMS), also known as lab-on-a-chip devices, for in vivo molecular sensing of tumor-associated biomolecules
  • Low-toxicity nanocrystal quantum dots for biomedical sensing

In addition to drawing on the scientific and technological expertise of its investigators, the Consortium uses available facilities for toxicology testing and the extensive mouse models of cancer collection at the collaborating institutions.

Project and Core Abstracts are available online:
NCI Alliance for Nanotechnology in Cancer, MIT-Harvard CCNE

Monthly Presentations for CCNE members (password protected):
CMIR Nanotechnology Program

Principal Investigators

Robert Langer, Ph.D.
Institute Professor
Massachusetts Institute of Technology

Ralph Weissleder, M.D., Ph.D.
Professor Harvard Medical School;
Director, Center for Molecular Imaging Research
Harvard University, Massachusetts General Hospital

In The News

Experts describe promise of nanotech for cancer detection, more
June 30, 2008

Hope on the horizon: Electrochemical Energy
May 21, 2008

Fantastic voyage: Drug delivery by a nanoparticle
February 13, 2008

Remote-control nanoparticles deliver drugs directly into tumors
November 20, 2007

HST device draws cells close – but not too close – together
April 4, 2007

Team develops nanoparticles to battle cancer
February 1, 2007

Tiny implants could offer huge insights on cancer
January 14, 2007

Scientific American names Angela Belcher Researcher of the Year
November 6 , 2006

Colleagues honor Langer for 30 years of innovation
July 20, 2006

MIT nanoparticles may help detect, treat tumors
May 1, 2006

Nanoparticles armed to combat cancer
April 10, 2006

Shrinking the war on cancer
October 31, 2005

MIT chosen for national role fighting cancer
October 4, 2005

Langer talk highlights cancer symposium
June 30, 2005